Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients

Table 4 Stratified analysis according to factors that could influence liver fibrosis

	TGF-β(ng/mL)	P value	HA (ng/mL)	P value
All patients
E (n = 30)	12.7 (3.7-133.6)	0.009	702.89 (329.4-838.2)	0.001
CNI (n = 30)	152.5 (14.4-333.2)		1513.6 (691.9-1951.4)
Free of neoplasia
E (n = 29)	11.1 (3.2-22.4)	0.005	754.8 (351.3-837)	0.030
CNI (n = 22)	137.5 (14.4-333.2)		1296.7 (703.7-1936.1)
Time from LT > 5 yr
E (n = 17)	16.5 (7.6-264.6)	0.010	462.0 (351.3-770.3)	0.002
CNI (n = 16)	296.8 (125.4-337.1)		1084.7 (523.7-1665.8)
Donor age > 50 yr
E (n = 12)	14.0 (6.0-67.1)	0.06	910.0 (589.2-1510.8)	0.005
CNI (n = 15)	96.0 (14.5-297.1)		1897.0 (1519-2136.5)
Biliary complications
E (n = 12)	20.6 (7.6-265)	0.110	516.75 (235.6-1079.4)	0.010
CNI (n = 10)	272.3 (16.5-403.4)		1545.37 (1085.8-1888.7)
Recurrent HCV
E (n = 10)	6.5 (1.6-15.3)	0.260	914.55 (768.8-1513.6)	0.410
CNI (n = 11)	14.5 ( 6.1-225)		1991.17 (1532.4-2168.9)

Variables are expressed as medians and interquartillic range. TGF-β: Transforming growth factor-β; HA: Hyaluronic acid; E: Everolimus; CNI: Calcineurin inhibitors.